P Glendenning

Summary

Affiliation: Western Australia
Country: Australia

Publications

  1. ncbi request reprint Vitamin D deficiency and multicultural Australia
    Paul Glendenning
    Med J Aust 176:242-3; author reply 243. 2002
  2. ncbi request reprint Diagnosis of primary hyperparathyroidism: controversies, practical issues and the need for Australian guidelines
    P Glendenning
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Wellington Street, Perth, Western Australia 6000, Australia
    Intern Med J 33:598-603. 2003
  3. doi request reprint Screening for vitamin D deficiency: defining vitamin D deficiency, target thresholds of treatment and estimating the benefits of treatment
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth, Western Australia, Australia
    Pathology 44:160-5. 2012
  4. doi request reprint Calculated free and bioavailable vitamin D metabolite concentrations in vitamin D-deficient hip fracture patients after supplementation with cholecalciferol and ergocalciferol
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth, Western Australia, Australia
    Bone 56:271-5. 2013
  5. doi request reprint Vitamin D: methods of 25 hydroxyvitamin D analysis, targeting at risk populations and selecting thresholds of treatment
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Australia
    Clin Biochem 45:901-6. 2012
  6. doi request reprint Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, PathWest Royal Perth Hospital, Perth, Western Australia 6000, Australia
    Bone 45:870-5. 2009
  7. doi request reprint Thyroxine autoantibody interference is an uncommon cause of inappropriate TSH secretion using the Immulite 2000 assay
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, PathWest, Laboratory Medicine W A, Royal Perth Hospital, Perth WA 6001, Australia
    Clin Chim Acta 403:136-8. 2009
  8. ncbi request reprint Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays
    P Glendenning
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth, Australia
    Ann Clin Biochem 43:23-30. 2006
  9. ncbi request reprint Issues of methodology, standardization and metabolite recognition for 25-hydroxyvitamin D when comparing the DiaSorin radioimmunoassay and the Nichols Advantage automated chemiluminescence protein-binding assay in hip fracture cases
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth 6000, Western Australia, Australia
    Ann Clin Biochem 40:546-51. 2003
  10. ncbi request reprint Parathyroid hormone is more stable in EDTA plasma than in serum
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth 6000, Western Australia
    Clin Chem 48:766-7. 2002

Collaborators

Detail Information

Publications25

  1. ncbi request reprint Vitamin D deficiency and multicultural Australia
    Paul Glendenning
    Med J Aust 176:242-3; author reply 243. 2002
  2. ncbi request reprint Diagnosis of primary hyperparathyroidism: controversies, practical issues and the need for Australian guidelines
    P Glendenning
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Wellington Street, Perth, Western Australia 6000, Australia
    Intern Med J 33:598-603. 2003
    ..Furthermore, critical appraisal of the new diagnostic criteria and their applicability to Australian laboratories will be addressed. Finally, limitations and problems associated with the measurement of each analyte will be reviewed...
  3. doi request reprint Screening for vitamin D deficiency: defining vitamin D deficiency, target thresholds of treatment and estimating the benefits of treatment
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth, Western Australia, Australia
    Pathology 44:160-5. 2012
    ..Finally, information needed by governments and health organisations to help justify population screening and what strategies could be adopted to make screening more cost-effective will be explored...
  4. doi request reprint Calculated free and bioavailable vitamin D metabolite concentrations in vitamin D-deficient hip fracture patients after supplementation with cholecalciferol and ergocalciferol
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth, Western Australia, Australia
    Bone 56:271-5. 2013
    ....
  5. doi request reprint Vitamin D: methods of 25 hydroxyvitamin D analysis, targeting at risk populations and selecting thresholds of treatment
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Australia
    Clin Biochem 45:901-6. 2012
    ..Until resolved, widespread adoption of screening programmes and measurement of 25OHD in patients at risk of non-musculoskeletal disease is premature, costly and not supported by evidence...
  6. doi request reprint Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, PathWest Royal Perth Hospital, Perth, Western Australia 6000, Australia
    Bone 45:870-5. 2009
    ..However, the lack of difference in PTH lowering between calciferol treatments raises questions about the biological importance of this observation...
  7. doi request reprint Thyroxine autoantibody interference is an uncommon cause of inappropriate TSH secretion using the Immulite 2000 assay
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, PathWest, Laboratory Medicine W A, Royal Perth Hospital, Perth WA 6001, Australia
    Clin Chim Acta 403:136-8. 2009
    ..T4 autoantibody (T4AAb) prevalence has not been determined. We determined the prevalence of inappropriate TSH secretion using the Immulite 2000 assay and the prevalence of T4AAb within this subgroup...
  8. ncbi request reprint Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays
    P Glendenning
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth, Australia
    Ann Clin Biochem 43:23-30. 2006
    ..Lack of standardization of these methods has resulted in inter-method disagreement and challenged whether current assays recognize 25(OH)D2 and 25(OH)D3 equally...
  9. ncbi request reprint Issues of methodology, standardization and metabolite recognition for 25-hydroxyvitamin D when comparing the DiaSorin radioimmunoassay and the Nichols Advantage automated chemiluminescence protein-binding assay in hip fracture cases
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth 6000, Western Australia, Australia
    Ann Clin Biochem 40:546-51. 2003
    ..The Nichols Advantage chemiluminescence protein-binding assay (CLPBA) for 25-OHD is a first-generation automated immunoassay with decreased turnaround time, reduced manual handling and non-radioactive label...
  10. ncbi request reprint Parathyroid hormone is more stable in EDTA plasma than in serum
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth 6000, Western Australia
    Clin Chem 48:766-7. 2002
  11. ncbi request reprint Preanalytical factors in the measurement of intact parathyroid hormone with the DPC IMMULITE assay
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, Royal Perth Hospital, Perth, WA 6000, Australia
    Clin Chem 48:566-7. 2002
  12. ncbi request reprint Fit for a fracture
    Hannah M Seymour
    Department of Geriatric Medicine, Royal Perth Hospital, GPO Box X2213, Perth, WA 6000, Australia
    Med J Aust 183:213-4. 2005
  13. doi request reprint Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence
    Charles A Inderjeeth
    University of Western Australia, Australia
    Bone 44:744-51. 2009
    ..Our search strategy included MeSH terms for osteoporosis and treatments. We reviewed the reference list of identified articles for additional relevant published trials...
  14. ncbi request reprint Prolonged vitamin D intoxication: presentation, pathogenesis and progress
    D A Bell
    Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, Western Australia, Australia School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia
    Intern Med J 43:1148-50. 2013
    ..Prolonged vitamin D toxicity can cause reversible hypercalcaemia and partially reversible renal impairment. Parathyroid hormone may not be suppressed with unactivated vitamin D toxicity, especially if renal disease coexists. ..
  15. doi request reprint Association between 25-OH vitamin D and insulin is independent of lipoatrophy in HIV
    E Hammond
    Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA, Australia
    Clin Endocrinol (Oxf) 76:201-6. 2012
    ....
  16. doi request reprint Association between 25-hydroxyvitamin D, somatic muscle weakness and falls risk in end-stage renal failure
    N Boudville
    School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia
    Clin Endocrinol (Oxf) 73:299-304. 2010
    ..We tested the hypothesis that 25OHD levels may be independently associated with falls risk in CKD-5D...
  17. doi request reprint Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009
    S Lee
    North Metropolitan Area Health Service, Perth, WA, Australia
    Osteoporos Int 22:741-53. 2011
    ..Adherence is complex and difficult to quantify and may not be exclusively influenced by frequency of medication administration...
  18. ncbi request reprint Vitamin D status and redefining serum PTH reference range in the elderly
    Paul Glendenning
    J Clin Endocrinol Metab 87:946-7. 2002
  19. ncbi request reprint Issues of standardization and assay-specific clinical decision limits for the measurement of 25-hydroxyvitamin D
    Paul Glendenning
    Am J Clin Nutr 77:522-3. 2003
  20. ncbi request reprint The estimated prevalence of familial hypocalciuric hypercalcemia (FHH)
    Paul Glendenning
    Calcif Tissue Int 70:512; author reply 512-3. 2002
  21. ncbi request reprint 8: Disorders of bone and mineral other than osteoporosis
    Richard L Prince
    Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia
    Med J Aust 180:354-9. 2004
    ..These disorders range from nutritional deficiencies to complex genetic and metabolic diseases..
  22. ncbi request reprint Estrogen and androgen regulation of plasma membrane calcium pump activity in immortalized distal tubule kidney cells
    Ian M Dick
    School of Medicine and Pharmacology, University of Western Australia, Nedlands, WA 6009, Australia
    Mol Cell Endocrinol 212:11-8. 2003
    ..and have significance for our understanding of estrogen and androgen deficient states on calcium transport...
  23. ncbi request reprint Low rate of compliance with ergocalciferol therapy in vitamin-D-deficient patients with hip fracture
    Jane M Noble
    Med J Aust 177:280. 2002
  24. ncbi request reprint Surgically correctable hypertension
    Paul Glendenning
    Pathology 34:297-8. 2002
  25. ncbi request reprint 25-OH-vitamin D assays
    Paul Glendenning
    J Clin Endocrinol Metab 90:3129. 2005